Inflammation in Duchenne results from a lack of dystrophin and, to date, steroids are the only approved therapy that address this facet of disease. This panel will discuss steroids, potential therapies aimed at reducing inflammation, and potential therapies that may work in combination with steroids.

Panelists:
ReveraGen BioPharma (Eric Hoffman, PhD, VP Research)
Catabasis Pharmaceuticals (Joanne M Donovan, MD PhD, Chief Medical Officer)
PTC Therapeutics (Brian E. Pfister, PhD, MBA, Executive Director, US Medical Head – Neurology)
Antisense Therapeutics (Gil Price, MD, Chief Medical Officer)

Followed by Q & A